· 機構(gòu)投資者 |
· 生物技術(shù)公司 |
· 私募股權(quán)投資者 |
· 投資銀行 |
· 風險資本家 |
· 經(jīng)紀公司 |
· 天使投資人 |
· 證券交易所 |
· 家庭辦公室 |
· 顧問及分析師 |
· 基金經(jīng)理 |
· 律師事務所 |
· 主要制藥公司 |
· CMOS和CRO |
第一天 2013年10月28日
|
第二天 2013年10月29日
|
| ||
08:30 |
登記及茶點招待 |
08:30
|
登記及茶點招待 |
|
09:00 |
歡迎及正式開幕
The Honourable Gordon Rich-Phillips MLC, Minister for Technology, State Government of Victoria
|
09:00 |
歡迎及正式開幕
Dr Fintan Walton, Founder and CEO, PharmaVentures |
|
09:10 |
會議主席致開場辭及交換名片
David Blake, Editor, Bioshares
|
09:15 |
生物技術(shù)融資和商業(yè)模式的發(fā)展
Kellee Kim, Research Analyst, ECOR1CAP
|
|
09:15 |
全球生物技術(shù)投資的趨勢和機會
Dr Eric Shiozaki, Director, Apposite Capital
|
09:35 |
經(jīng)紀專題:生命科學個股票展望
Dr Fintan Walton, Founder and CEO, PharmaVentures
Joanna Hill, Client Services Manager, EL & C Baillieu Stockbroking
Steven Yatomi-Clarke, Director Corporate Finance, Patersons Securities
Sam Street, Associate Director Corporate Finance, RBS Morgans
James Posnett, Manager, Listing Business Development, ASX
|
|
09:35 |
探索不斷發(fā)展的生物技術(shù)投資環(huán)境——挑戰(zhàn)和機會
David Blake, Editor, Bioshares
Dr Jonathan Wang, Senior Managing Director, Orbimed Asia
Jeremy Curnock Cook, Managing Director, Bioscience Managers
Scott Power, Director of Research, RBS Morgans
Dr Joshua Funder, Partner, GBS Venture Partners |
|||
10:15 |
生物技術(shù)公司聚焦介紹
Julie Phillips, CEO, BioDiem
Dr John Holaday, Managing Director, CEO and CSO, QRxPharma
Dr Brad Walsh, CEO, Minomic International
Dr Greg Collier, CEO, Invion
Howard Digby, Executive Director, EcoQuest
|
10:15 |
生物技術(shù)公司聚焦介紹
Geoffrey Kempler, Executive Chairman, Prana Biotechnology
Dr Tom McCarthy, CEO & Managing Director, Spinifex Pharmaceuticals
Roger McPherson, CFO, Patrys
Dr Geoff Cumming, CEO, Anteo Diagnostics
Dr Cliff Holloway, CEO, Immune System Therapeutics
|
|
11:00
|
早茶 |
11:00 |
早茶 |
|
11:30 |
改變中的生物技術(shù)投資環(huán)境
David Blake, Editor, Bioshares
Lawrence Gozlan, Chief Investment Officer and Founder, Scientia Capital
Michael Glenane, Executive Director, Fairview Equity Partners
John Granger, Founder, Hawkesbury Partners
Graeme Colley, Director of Technical and Professionals Standards, Self Managed Super Funds Professionals’ Association of Australia
Ron Laufer, Senior Managing Director, Medimmune Ventures
|
11:30 |
澳大利亞維多利亞省州的生物技術(shù)產(chǎn)業(yè)能力
Representative, Victorian Government
|
|
12:00 |
集資和投資而做知識產(chǎn)權(quán)盡職調(diào)查 |
|||
12:30 |
生物技術(shù)公司聚焦介紹
Simon Wilkinson, Director & CEO, Innate Immunotherapeutics
Nick Weston, Chairman & CEO, Agenix
Mike Thomas, CEO, iSonea
Marc Storms, Marketing Manager, FEI
|
|||
12:15 |
生物技術(shù)公司聚焦介紹
Dr Deborah Rathjen, CEO, Bionomics
Dr Paul MacLeman, CEO, IDT Australia
Dr Malcolm McColl, CEO, Viralytics
Dr Michelle Miller, CEO, Biotron
Charles Walker, CEO, Alchemia
|
13:05 |
午餐 |
|
14:15 |
亞洲區(qū)在生物技術(shù)創(chuàng)新和投資的角色越發(fā)壯大
Dr Jason Mann, Managing Director, Fenex Capital Management
|
|||
13:00 |
午餐 |
14:35 |
如何引入中國投資?
Dr Fintan Walton, Founder and CEO, PharmaVentures
Rob Scott, Director, China Bluesky Ventures
Dr Benjamin Chen, Managing Partner, Ignatius Transaction Partners
David Cheng, Chief Investment Officer, Coland Holdings
Dr Jason Mann, Managing Director, Fenex Capital Management
|
|
14:00 |
衡量生物技術(shù)的機會,并優(yōu)化投資回報率
Dr Michael A. Berry, Managing Director, Discovery Investing
|
|||
14:20 |
醫(yī)藥專題:組成戰(zhàn)略伙伴達至長期的成功
David Blake, Editor, Bioshares
Augustine Yee, Asia Pacific Head of Regional and Corporate Business Development and China Vice President of Business Development, AstraZeneca
Dr James Garner, Vice President & General Manager, Takeda Global Research & Development Centre Asia, Takeda
Dr Martin Judge, Director, Strategy and Sourcing, Novo Nordisk A/S
Dr Brian Bloomquist, Senior Director, Global External Research and Development, Eli Lilly
Dr Raman Rao, Head External R&D, Asia Pacific, Sanofi Pasteur
|
|||
15:05 |
生物技術(shù)公司聚焦介紹
Uwe Schlokat, CEO, Sentinext Therapeutics
Mark Heffernan, Chief Executive Officer, Nexvet Biopharma
Nick Ede, Executive Director, Imugene
Dr Clement Leong, Chief Executive Officer, Ascend Biopharmaceuticals
|
|||
15:00 |
生物技術(shù)公司聚焦介紹
Carl Stubbing, Chief Business Officer, Benitec Biopharma
Dr Julian Chick, COO, Allied Healthcare Group
Dr Andrea Grant, CEO, Living Cell Technologies
Mark Diamond, Managing Director & CEO, Antisense Therapeutics |
15:40 |
下午茶 |
|
16:00 |
分拆創(chuàng)造價值
Dr Fintan Walton, Founder and CEO, PharmaVentures
Dr Chris Nave, Chief Executive Officer, Medical Research Commercialisation Fund
Dr John Kurek, Investment Manager, Uniseed Ventures
Dr Mel Billingsley, President and CEO, The Life Sciences Greenhouse of Central Pennsylvania
Ron Laufer, Senior Managing Director, Medimmune Ventures |
|||
15:35 |
下午茶 |
|||
16:00 |
贏得在澳大利亞投資的稅后回報——策略和機會
Helen Fisher, Corporate & International Tax Partner, Deloitte
Sergio Duchini, R&D & Government Incentives Partner, Deloitte |
|||
16:30 |
生物技術(shù)公司聚焦介紹
Dr Richard Hopkins, CEO, Phylogica
Paul Wright, CEO, Universal Biosensors
|
|||
16:45 |
分析員圓桌會議:分析生物技術(shù)熱潮
David Blake, Editor, Bioshares
Marc Sinatra, Equities Analyst, Lodge Partners
Dr Graeme Wald, Investment Director, Bioscience Managers
Scott Power, Director of Research, RBS Morgans
Dr Matthijs Smith, Senior Analyst, Canaccord Genuity
|
16:50 |
生物技術(shù)在未來10年的挑戰(zhàn)和投資機會
Dr Fintan Walton, Founder and CEO, PharmaVentures
Glenn Cross, Chief Operating Officer, AusBiotech
Todd Davis, Managing Director, Healthcare Royalty Partners
Eric Shiozaki, Director, Apposite Capital
Rhenu Bhuller, Global Vice President Pharmaceuticals/Biotechnology, Frost & Sullivan
Dr Stewart Washer, Chairman, iSonea
|
|
17:30 |
第一天會議結(jié)束及招待酒會 |
17:30 |
主席致閉幕詞,會議結(jié)束 |